Autolus Therapeutics Stock Performance
| AUTL Stock | USD 2.12 0.03 1.40% |
On a scale of 0 to 100, Autolus Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 1.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Autolus Therapeutics will likely underperform. Please check Autolus Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Autolus Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Autolus Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating basic indicators, Autolus Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 240.3 M |
Autolus Therapeutics Relative Risk vs. Return Landscape
If you would invest 182.00 in Autolus Therapeutics on March 16, 2025 and sell it today you would earn a total of 30.00 from holding Autolus Therapeutics or generate 16.48% return on investment over 90 days. Autolus Therapeutics is currently generating 0.4375% in daily expected returns and assumes 6.3252% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Autolus, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Autolus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Autolus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Autolus Therapeutics, and traders can use it to determine the average amount a Autolus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0692
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AUTL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.33 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Autolus Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Autolus Therapeutics by adding it to a well-diversified portfolio.
Autolus Therapeutics Fundamentals Growth
Autolus Stock prices reflect investors' perceptions of the future prospects and financial health of Autolus Therapeutics, and Autolus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Autolus Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (7.26) % | ||||
| Current Valuation | 137.28 M | ||||
| Shares Outstanding | 266.14 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 63.50 X | ||||
| Revenue | 10.12 M | ||||
| EBITDA | (182.42 M) | ||||
| Cash And Equivalents | 216.44 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 52.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Book Value Per Share | 1.39 X | ||||
| Cash Flow From Operations | (206.27 M) | ||||
| Earnings Per Share | (0.84) X | ||||
| Total Asset | 782.73 M | ||||
| Retained Earnings | (1.1 B) | ||||
| Current Asset | 102.22 M | ||||
| Current Liabilities | 6.46 M | ||||
About Autolus Therapeutics Performance
By examining Autolus Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Autolus Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Autolus Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people.Things to note about Autolus Therapeutics performance evaluation
Checking the ongoing alerts about Autolus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Autolus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Autolus Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 10.12 M. Net Loss for the year was (220.66 M) with loss before overhead, payroll, taxes, and interest of (146.02 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (206.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Squarepoint Ops LLC Acquires Shares of 43,640 Ikena Oncology, Inc. - Defense World |
- Analyzing Autolus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Autolus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Autolus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Autolus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Autolus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Autolus Therapeutics' stock. These opinions can provide insight into Autolus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.